Vincera Pharma, Inc.(VINC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VINC Vincera Pharma, Inc.

Trading 11-05 11:32:19 EST

0.3500

-0.0080

-2.23%

High0.3599	Low0.3400	Vol243.92K
Open0.3473	D1 Closing0.3580	Amplitude5.56%
Mkt Cap10.81M	Tradable Cap8.62M	Total Shares30.88M
T/O84.94K	T/O Rate0.99%	Tradable Shares24.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VINC","market":"US","secType":"STK","nameCN":"Vincera Pharma, Inc.","latestPrice":0.35,"timestamp":1730824192568,"preClose":0.358,"halted":0,"volume":243920,"delay":0,"floatShares":24635922,"shares":30880903,"eps":-1.100726,"marketStatus":"Trading","change":-0.008,"latestTime":"11-05 11:32:19 EST","open":0.3473,"high":0.3599,"low":0.34,"amount":84935.212456,"amplitude":0.055587,"askPrice":0.3599,"askSize":201,"bidPrice":0.346,"bidSize":3100,"shortable":3,"etf":0,"ttmEps":-1.100726,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1730840400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.358,"preHourTrading":{"tag":"盘前","latestPrice":0.36,"preClose":0.358,"latestTime":"08:30 EST","volume":532,"amount":191.51999999999998,"timestamp":1730813414740},"postHourTrading":{"tag":"盘后","latestPrice":0.342,"preClose":0.358,"latestTime":"18:10 EST","volume":188,"amount":65.4255,"timestamp":1730761810911},"volumeRatio":2.548464},"requestUrl":"/m/hq/s/VINC","defaultTab":"news","newsList":[{"id":"2473477220","title":"Vincerx Pharma Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2473477220","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473477220?lang=en_us&edition=fundamental","pubTime":"2024-10-08 23:57","pubTimestamp":1728403020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VINC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 08, 2024 11:57 ET (15:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VINC"],"gpt_icon":0},{"id":"2473471822","title":"Vincerx stock tumbles 20% on corporate updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2473471822","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473471822?lang=en_us&edition=fundamental","pubTime":"2024-10-08 22:28","pubTimestamp":1728397712,"startTime":"0","endTime":"0","summary":"Vincerx (NASDAQ:VINC) shares were down 20% in morning trading Tuesday after the biotech company said it plans to seek out strategic partners for two of its drug candidates so that it can focus its res","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325961728/image_1325961728.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325961728/image_1325961728.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4157023-vincerx-stock-tumbles-on-corporate-updates","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["VINC","BK4139"],"gpt_icon":0},{"id":"2473422815","title":"Vincerx Pharma Inc : Leerink Partners Cuts Target Price to $2 From $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2473422815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473422815?lang=en_us&edition=fundamental","pubTime":"2024-10-08 20:56","pubTimestamp":1728392194,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241008:nFWN3LK0S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VINC"],"gpt_icon":0},{"id":"2473439200","title":"Vincerx Pharma Reports 'Positive' Initial Clinical Data on Leukemia Drug; Shares Jump After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2473439200","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473439200?lang=en_us&edition=fundamental","pubTime":"2024-10-08 05:05","pubTimestamp":1728335132,"startTime":"0","endTime":"0","summary":"Vincerx Pharma (VINC) said its VIP943 leukemia drug showed \"promising safety and tolerability,\" achieving two complete responses to date in a phase 1 dose-escalation studyThe VIP943 antibody-drug conj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VINC","BK4139"],"gpt_icon":0},{"id":"2473435281","title":"BRIEF-Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study And Provides Pipeline And Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2473435281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473435281?lang=en_us&edition=fundamental","pubTime":"2024-10-08 04:27","pubTimestamp":1728332853,"startTime":"0","endTime":"0","summary":"Vincerx Pharma Inc   :   * VINCERX REPORTS POSITIVE INITIAL CLINICAL DATA FROM ONGOING VIP943 PHASE 1 DOSE-ESCALATION STUDY AND PROVIDES PIPELINE AND CORPORATE UPDATES   * VINCERX PHARMA INC - EXPECTED CASH RUNWAY INTO EARLY 2025   * VINCERX PHARMA INC - VINCERX FOCUSING RESOURCES ON CONTINUED DEVELOPMENT OF VIP943   * VINCERX PHARMA INC - VIP943 DEMONSTRATES PROMISING SAFETY AND TOLERABILITY AND ACHIEVES TWO COMPLETE RESPONSES TO DATE IN PHASE 1 DOSE-ESCALATION STUDY   * VINCERX PHARMA INC - ANTICIPATES PROVIDING ANOTHER DATA UPDATE ON ONGOING PHASE 1 VIP943 STUDY BY END OF YEAR.Source text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VINC","BK4139"],"gpt_icon":0},{"id":"2473433903","title":"Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2473433903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473433903?lang=en_us&edition=fundamental","pubTime":"2024-10-08 04:05","pubTimestamp":1728331501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241007:nTUA3NHNMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VINC","BK4139"],"gpt_icon":0},{"id":"2473433172","title":"Vincerx Pharma Inc - Expected Cash Runway Into Early 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2473433172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473433172?lang=en_us&edition=fundamental","pubTime":"2024-10-08 04:05","pubTimestamp":1728331501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241007:nTUA3NHNMV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VINC","BK4139"],"gpt_icon":0},{"id":"2473433170","title":"Vincerx Pharma Inc - Vincerx Focusing Resources on Continued Development of Vip943","url":"https://stock-news.laohu8.com/highlight/detail?id=2473433170","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473433170?lang=en_us&edition=fundamental","pubTime":"2024-10-08 04:05","pubTimestamp":1728331501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241007:nTUA3NHNMV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VINC","BK4139"],"gpt_icon":0},{"id":"2473331034","title":"Vincerx Pharma Inc - Anticipates Providing Another Data Update on Ongoing Phase 1 Vip943 Study by End of Year.","url":"https://stock-news.laohu8.com/highlight/detail?id=2473331034","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473331034?lang=en_us&edition=fundamental","pubTime":"2024-10-08 04:05","pubTimestamp":1728331501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241007:nTUA3NHNMV:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VINC","BK4139"],"gpt_icon":0},{"id":"2473106433","title":"Vincerx Pharma Inc - Vip943 Demonstrates Promising Safety and Tolerability and Achieves Two Complete Responses to Date in Phase 1 Dose-Escalation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2473106433","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473106433?lang=en_us&edition=fundamental","pubTime":"2024-10-08 04:05","pubTimestamp":1728331501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241007:nTUA3NHNMV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VINC","BK4139"],"gpt_icon":0},{"id":"2460221010","title":"Vincerx Pharma Announces Stock Option Repricing and Shareholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2460221010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460221010?lang=en_us&edition=fundamental","pubTime":"2024-08-17 04:32","pubTimestamp":1723840326,"startTime":"0","endTime":"0","summary":"Vincerx Pharma Inc (VINC) has shared an update. Vincerx Pharma, Inc. has implemented a one-time stock option repricing and exchange program, effect...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vincerx-pharma-announces-stock-option-repricing-and-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vincerx-pharma-announces-stock-option-repricing-and-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VINC"],"gpt_icon":0},{"id":"2458356926","title":"Vincerx Pharma GAAP EPS of -$0.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2458356926","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458356926?lang=en_us&edition=fundamental","pubTime":"2024-08-09 19:25","pubTimestamp":1723202702,"startTime":"0","endTime":"0","summary":"Vincerx Pharma press release  (NASDAQ:VINC): Q2  GAAP EPS of -$0.05.\nVincerx had approximately $16.3 million in cash, cash equivalents and marketable securities as of June 30, 2024, as compared to approximately $5.1 million as of March 31, 2024.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4137950-vincerx-pharma-gaap-eps-of-0_05","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QLD","TQQQ","VINC","QID","SQQQ","MNQmain",".IXIC","PSQ","NQmain","BK4139"],"gpt_icon":1},{"id":"2458737437","title":"Vincerx Pharma Inc reports results for the quarter ended in January - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2458737437","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458737437?lang=en_us&edition=fundamental","pubTime":"2024-08-09 06:47","pubTimestamp":1723157226,"startTime":"0","endTime":"0","summary":"* Vincerx Pharma Inc    reported a quarterly adjusted loss of 5 cents per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of -52 cents.  T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vincerx Pharma Inc reports results for the quarter ended in January - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VINC"],"gpt_icon":0},{"id":"2458379382","title":"Vincerx Pharma Q2 EPS $(0.05) Up From $(0.54) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2458379382","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458379382?lang=en_us&edition=fundamental","pubTime":"2024-08-09 06:10","pubTimestamp":1723155024,"startTime":"0","endTime":"0","summary":"Vincerx Pharma Q2 EPS $(0.05) Up From $(0.54) YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40271959/vincerx-pharma-q2-eps-0-05-up-from-0-54-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vincerx Pharma Q2 EPS $(0.05) Up From $(0.54) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VINC"],"gpt_icon":0},{"id":"2458837610","title":"Vincerx Pharma Inc: Expected Cash Runway Through 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2458837610","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458837610?lang=en_us&edition=fundamental","pubTime":"2024-08-09 04:30","pubTimestamp":1723149001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240808:nTUA454NCY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VINC","BK4139"],"gpt_icon":0},{"id":"2458332735","title":"Vincerx Pharma Q2 Basic EPS USD -0.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2458332735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458332735?lang=en_us&edition=fundamental","pubTime":"2024-08-09 04:30","pubTimestamp":1723149001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240808:nPLX31A012:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["USD","BK4139","BAS","VINC"],"gpt_icon":0},{"id":"2458327876","title":"Vincerx Pharma Q2 Net Income USD -1.808 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2458327876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458327876?lang=en_us&edition=fundamental","pubTime":"2024-08-09 04:30","pubTimestamp":1723149001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240808:nPLX31A012:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","USD","VINC"],"gpt_icon":0},{"id":"2458322175","title":"Press Release: Vincerx Pharma Reports Second Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2458322175","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458322175?lang=en_us&edition=fundamental","pubTime":"2024-08-09 04:30","pubTimestamp":1723149000,"startTime":"0","endTime":"0","summary":"Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate  VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate  VIP236, with data expected at the end of Q3 2024. PALO ALTO, Calif., Aug. 08, 2024  -- Vincerx Pharma, Inc. , a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the second quarter of 2024 and provided an overview of its clinical programs and anticipated milestones.\"During the second quarter, our team focused on execution and the continued enrollment of patients in our ongoing Phase 1 studies for our potentially best-in-class ADC, VIP943, and first-in-class SMDC, VIP236,\" said Ahmed Hamdy, M.D., Chief Executive Officer. \"We look forward to evaluating the results from additional cohorts and sharing data by end of Q3 for VIP236 and by end of year for VIP943.\". platform, consists of an anti-CD123 antibody, a uni","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","ADC","CPT","BK4099","BK4231","R","TM","BK4215","BK4232","BK4022","03160","VINC","BK4585","BK4555","BK4139","BK4588"],"gpt_icon":0},{"id":"2447628686","title":"Why Is Applied Therapeutics, Inc. (APLT) the Best Biotech Penny Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2447628686","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2447628686?lang=en_us&edition=fundamental","pubTime":"2024-06-30 08:50","pubTimestamp":1719708638,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Applied Therapeutics, Inc.  stands against the other biotech penny stocks.Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities. In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities. Particularly biotech is anticipated to profit, despite the dangers of continuous mergers and acquisitions. Traders ought to exercise caution. With an 11.8% CAGR, the worldwide biotechnology market is expected to reach USD 4.25 trillion by 2033. It is expanding quickly. The U.S. market is projected to increase at an 11.90% CAGR to reach USD 763.82 billion by 2033 from its 2023 valuation of USD 246.18 billion. In 2023, the U.S. led North America in terms of revenue share.\"[Biotech] has been one of the worst spaces in all of the equity market since mid-2021. We've barely seen any positi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nzk2aeegYaje.LiEf3oHDQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/bd2d9661f11e728786ccfadde88fc62e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nzk2aeegYaje.LiEf3oHDQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/bd2d9661f11e728786ccfadde88fc62e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-applied-therapeutics-inc-aplt-005038160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","VINC","LU0320765992.SGD","QID","LU0109394709.USD","PSQ","APLT","NQmain","SQQQ","LU0889565916.HKD","CRBP","MNQmain","BK4139","QQQ","BK4588","TQQQ","VKTX",".IXIC","BK4585"],"gpt_icon":1},{"id":"2447764000","title":"Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2447764000","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2447764000?lang=en_us&edition=fundamental","pubTime":"2024-06-30 08:48","pubTimestamp":1719708491,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Annexon, Inc.  stands against the other biotech penny stocks.Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities. In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities. Particularly biotech is anticipated to profit, despite the dangers of continuous mergers and acquisitions. Traders ought to exercise caution. With an 11.8% CAGR, the worldwide biotechnology market is expected to reach USD 4.25 trillion by 2033. It is expanding quickly. The U.S. market is projected to increase at an 11.90% CAGR to reach USD 763.82 billion by 2033 from its 2023 valuation of USD 246.18 billion. In 2023, the U.S. led North America in terms of revenue share.\"[Biotech] has been one of the worst spaces in all of the equity market since mid-2021. We've barely seen any positive activity f","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bBRdjYGEWjMZYaSegmm1CA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/dd58c6fc02855acc6074dc830fcb1af0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bBRdjYGEWjMZYaSegmm1CA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/dd58c6fc02855acc6074dc830fcb1af0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/analysts-bullish-annexon-inc-annx-004811797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QQQ","BK4585","SQQQ","TQQQ","PSQ","BK4588","ANNX","VKTX",".IXIC","NQmain","BK4139","QID","VINC","MNQmain","QLD","CRBP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vincerx.com","stockEarnings":[{"period":"1week","weight":-0.0389},{"period":"1month","weight":-0.5096},{"period":"3month","weight":-0.3828},{"period":"6month","weight":-0.5687},{"period":"1year","weight":-0.6309},{"period":"ytd","weight":-0.6966}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.052279},{"month":2,"riseRate":0.5,"avgChangeRate":0.336738},{"month":3,"riseRate":0.25,"avgChangeRate":0.00871},{"month":4,"riseRate":0.25,"avgChangeRate":-0.275732},{"month":5,"riseRate":0.25,"avgChangeRate":-0.081376},{"month":6,"riseRate":0.2,"avgChangeRate":-0.067243},{"month":7,"riseRate":0.6,"avgChangeRate":-0.056825},{"month":8,"riseRate":0.6,"avgChangeRate":0.031662},{"month":9,"riseRate":0.6,"avgChangeRate":0.11529},{"month":10,"riseRate":0.2,"avgChangeRate":-0.141886},{"month":11,"riseRate":0.4,"avgChangeRate":-0.160042},{"month":12,"riseRate":0.75,"avgChangeRate":0.3778}],"exchange":"NASDAQ","name":"Vincera Pharma, Inc.","nameEN":"Vincera Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vincera Pharma, Inc.(VINC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vincera Pharma, Inc.(VINC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vincera Pharma, Inc.,VINC,Vincera Pharma, Inc.股票,Vincera Pharma, Inc.股票老虎,Vincera Pharma, Inc.股票老虎国际,Vincera Pharma, Inc.行情,Vincera Pharma, Inc.股票行情,Vincera Pharma, Inc.股价,Vincera Pharma, Inc.股市,Vincera Pharma, Inc.股票价格,Vincera Pharma, Inc.股票交易,Vincera Pharma, Inc.股票购买,Vincera Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vincera Pharma, Inc.(VINC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vincera Pharma, Inc.(VINC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}